Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn’t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.

Person using mobile app and screenshot of app interface © MORU 2020. Photographer: Supa-at (Ice) Asarath.
COPCOV participants will use a mobile app to report their health daily.
Load More

Similar stories

Children with acute malnutrition and malaria: the double burden that increases risk of treatment failure

An analysis of over 11,000 falciparum malaria individual patient data sets has found that acutely malnourished children have a higher risk of reinfections and treatment failures, even when treated with recommended doses of artemisinin-based combination therapies, currently the best malaria treatment available. The malaria parasite clearance was also likely to be longer in these children.